Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06355531 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: estimated 220 to confirmed 241v19
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 44 of 44 sites
    v18
  3. Re-verified, no change to tracked fieldsv17
  4. Site contacts updated at 33 of 44 sitesv16
  5. Study sites: 42 to 44v15
Show 13 earlier versionsHide 13 earlier versions
  1. Study sites: 41 to 42v14
  2. Site contacts updated at 3 of 41 sitesv13
  3. Study sites: 39 to 41v12
  4. Study sites: 36 to 39v11
  5. Study sites: 29 to 36
    • Eligibility criteria expanded, about 17 words
    v10
  6. Study sites: 23 to 29v9
  7. Study sites: 16 to 23v8
  8. Study sites: 8 to 16
    • Eligibility criteria expanded, about 3 words
    v7
  9. Study sites: 6 to 8v6
  10. Study sites: 5 to 6v5
  11. Study sites: 4 to 5v4
  12. Start date changed from estimate of Jun 2024 to Jul 23, 2024
    • Site contacts updated at 1 of 4 sites
    v3
  13. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Apr 2024 to Jun 2024
    • Study sites: 0 to 4
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.
Trial Details
NCT Number NCT06355531
Lead Sponsor Ferrer Internacional S.A.
Conditions
(from sponsor)		 Progressive Supranuclear Palsy
Related terms Disease Progression, Supranuclear Palsy, Progressive
Enrollment 241 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov